BusinessCathieFunds

Cathie Wood’s Ark Funds Built Up Big Stakes in Crispr. The Stock Is Now Tumbling.


We’ve detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser.



We’ve detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser.GoogleFirefox

barrons logo

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/cathie-woods-ark-funds-crispr-51634129432


  • Order Reprints

  • Print Article

Crispr Therapeutics stock was tumbling Wednesday, after the results of an experimental treatment from the gene-based medicine specialist underwhelmed investors. 

That is bad news for high-profile investor Cathie Wood, whose Ark Investment Management recently bought shares in the biotech company for two of its actively managed exchange-traded funds (ETFs). 

The…


Cathie Wood’s Ark Funds Built Up Big Stakes in Crispr. The Stock Is Now Tumbling.

Crispr Therapeutics stock was tumbling Wednesday, after the results of an experimental treatment from the gene-based medicine specialist underwhelmed investors.

An error has occurred, please try again later.

Thank you

This article has been sent to

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close
Close